Clinical Trial Update: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial assessing safety, tolerability, and preliminary antitumor activity of Sitravatinib plus Tislelizumab or with Nab-paclitaxel in metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)
• Sitravatinib (sitravatinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: UNKNOWN